Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Congress 2024

26 - 28 Feb 2024

Paris, France

ESMO-TAT-2024-1000x1000

Abstracts and ePosters: Open Access
Slides and Webcasts: Available to ESMO Members and registered delegates, subject to presenters' consent

The copyright protected educational resources from this event are for personal usage only and not to be shared with any third parties. ESMO thanks the authors for their generosity.

ESMO TAT offered participants a glimpse into the future of anticancer therapies, focusing on promising new targets and early drug development.
The expanded programme, including four new special sessions with industry addressing drug development, methodological, regulatory, strategic financing and investment issues, offered a fresh, wide-ranging perspective on the development of innovative anticancer therapeutics and their optimal implementation.

Abstract book in ESMO Open

Abstracts and all resources are published!

Use the search box below to type any keywords, or the abstract number.

Hide
Filter by:

There are 169 resources available

Panel discussion

Presenter: All Speakers

Session: The quest for dosage and combination optimisation in early drug development

Resources:

Webcast

Q&A and discussion

Presenter: All Speakers

Session: Next generation cell cycle inhibitors and role of biomarker selection

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.